Evaluation of two strategies for the interpretation of tumour markers in pleural effusions

BackgroundPleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions: a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers – ADA, CRP and % of polymorphonuclear cells – improves diagnostic accuracy.MethodsWe studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum.ResultsEstablishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio.ConclusionsThe best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers.

[1]  Gang Huang,et al.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21‐1 in patients with pleural effusion: a systematic review and meta‐analysis , 2007, Journal of clinical laboratory analysis.

[2]  M. Pelegrí,et al.  Adenosine deaminase in body fluids: a useful diagnostic tool in tuberculosis. , 1989, Clinical biochemistry.

[3]  J. G. García Díaz,et al.  Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. , 2008, Anticancer research.

[4]  W. Hsu,et al.  Role of Pleural Fluid C-Reactive Protein Concentration in Discriminating Uncomplicated Parapneumonic Pleural Effusions from Complicated Parapneumonic Effusion and Empyema , 2006, Lung.

[5]  A. Gozu,et al.  Tumour necrosis factor-alpha in comparison to adenosine deaminase in tuberculous pleuritis. , 2003, Respiration; international review of thoracic diseases.

[6]  V. Villena,et al.  Diagnostic value of CA 72‐4, carcinoembryonic antigen, CA 15‐3, and CA 19‐9 assay in pleural fluid: A study of 207 patients , 1996, Cancer.

[7]  A. Chaiprasert,et al.  A simple C‐reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion , 2004, Respirology.

[8]  J. M. Porcel,et al.  Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. , 2004, Chest.

[9]  R. Molina,et al.  Diagnostic accuracy of tumour markers in serous effusions: a validation study , 2012, Tumor Biology.

[10]  M. Soler,et al.  C-Reactive Protein in Lymphocytic Pleural Effusions: A Diagnostic Aid in Tuberculous Pleuritis , 2005, Respiration.

[11]  R. Krenke,et al.  Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions , 2009, European journal of medical research.

[12]  Castaño Vidriales Jl,et al.  Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions. , 1992 .

[13]  E. Garcia-Pachon,et al.  Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. , 1997, Chest.

[14]  E. Felip,et al.  Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures. , 2007, QJM : monthly journal of the Association of Physicians.

[15]  J. L. Castaño Vidriales,et al.  Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions. , 1992, The European journal of medicine.

[16]  R. Light,et al.  Clinical practice. Pleural effusion. , 2002, The New England journal of medicine.

[17]  Kan Zhai,et al.  Diagnostic accuracy of tumor markers for malignant pleural effusion: a , 2007 .

[18]  J. M. Porcel,et al.  Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. , 2014, Archivos de bronconeumologia.

[19]  R. Molina,et al.  Clinical Evaluation of the Simultaneous Determination of Tumor Markers in Fluid and Serum and Their Ratio in the Differential Diagnosis of Serous Effusions , 2004, Tumor Biology.

[20]  E. Garcia-Pachon,et al.  Diagnostic value of C-reactive protein in exudative pleural effusions. , 2002, European journal of internal medicine.

[21]  X. Filella,et al.  Increased plasma concentrations of tumour markers in the absence of neoplasia , 2011, Clinical chemistry and laboratory medicine.

[22]  W. Roberts,et al.  Performance characteristics of seven automated CA 15-3 assays. , 2006, American journal of clinical pathology.

[23]  A. Gozu,et al.  Tumour Necrosis Factor-α in Comparison to Adenosine Deaminase in Tuberculous Pleuritis , 2003, Respiration.

[24]  E. Felip,et al.  Diagnostic utility of CYFRA 21‐1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions , 1999, Cancer.

[25]  Hai‐Bo Yang,et al.  Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta‐analysis , 2008, Respirology.

[26]  H. Lee,et al.  The implication of elevated carcinoembryonic antigen level in pleural fluid of patients with non‐malignant pleural effusion , 2003, Respirology.

[27]  J. M. Porcel,et al.  Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas , 2014 .

[28]  V. Villena,et al.  Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. , 2003, Lung cancer.